{"DataElement":{"publicId":"6831339","version":"1","preferredName":"Prostatic Tissue Estimated Tumor Involvement Percentage Value","preferredDefinition":"Numeric representation of the estimated percentage of prostatic tissue involved by tumor.","longName":"6829700v1.0:2903088v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6829700","version":"1","preferredName":"Prostatic Tissue Estimate Malignant Neoplasm Involvement","preferredDefinition":"Tissue composed of tubuloalveolar glands embedded in fibromuscular stroma. The stroma is smooth muscle separated by strands of connective tissue rich in collagenous and elastic fibers. The secretory alveoli of the prostate are irregularly shaped with papillary projections of the mucosa into the lumen of the gland._To calculate approximately._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._To have a connection by participation or association or use; sharing in an activity or process.","longName":"6829697v1.0:6829698v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"6829697","version":"1","preferredName":"Prostatic Tissue","preferredDefinition":"Tissue composed of tubuloalveolar glands embedded in fibromuscular stroma. The stroma is smooth muscle separated by strands of connective tissue rich in collagenous and elastic fibers. The secretory alveoli of the prostate are irregularly shaped with papillary projections of the mucosa into the lumen of the gland.","longName":"C33414","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostatic Tissue","conceptCode":"C33414","definition":"Tissue composed of tubuloalveolar glands embedded in fibromuscular stroma. The stroma is smooth muscle separated by strands of connective tissue rich in collagenous and elastic fibers. The secretory alveoli of the prostate are irregularly shaped with papillary projections of the mucosa into the lumen of the gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E86499D-F6CD-72CC-E053-F662850A1FFE","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6829698","version":"1","preferredName":"Estimate Malignant Neoplasm Involvement","preferredDefinition":"To calculate approximately.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:To have a connection by participation or association or use; sharing in an activity or process.","longName":"C25498:C9305:C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estimate","conceptCode":"C25498","definition":"To calculate approximately.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E86499D-F6DF-72CC-E053-F662850A1FFE","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E86499D-F6F0-72CC-E053-F662850A1FFE","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-25","modifiedBy":"COOPERM","dateModified":"2019-08-19","changeDescription":"Created for Prostate Cancer request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2903088","version":"1","preferredName":"Percentage Value","preferredDefinition":"A numerical quantity measured or assigned or computed that is a fraction or ratio with 100 understood as the denominator.","longName":"PER_VAL","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208119","version":"1","preferredName":"Percentage Value","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3E46-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6CB91576-373C-243B-E040-BB89AD43311A","latestVersionIndicator":"Yes","beginDate":"2009-06-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-06-19","modifiedBy":"COOPERM","dateModified":"2019-04-17","changeDescription":"10/23/18 jk chg reg status to Standard as part of RECIST FG content; reused by 30 CDEs and multiple SOs. 10-19-2018 TMT received permission from BC to transfer ownership from NIDCR to NCI Standards.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000016","version":"1","longName":"Prostate","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"For enucleation and other spe","type":"Preferred Question Text","description":"For enucleation and other specimens, estimated percentage of prostatic tissue involved by tumor","url":null,"context":"OCG"},{"name":"For enucleation specimens, estimated percentage of prostatic tissue involved by tumor","type":"Alternate Question Text","description":"For enucleation specimens, estimated percentage of prostatic tissue involved by tumor","url":null,"context":"OCG"},{"name":"Alt_For enucleation specimens, estimated percentage of prostatic tissue involved by tumor","type":"Alternate Question Text","description":"For enucleation specimens, estimated percentage of prostatic tissue involved by tumor","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85CB4E-2240-71E7-E053-F662850A80C0","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-25","modifiedBy":"HARTLEYG","dateModified":"2019-09-23","changeDescription":"Created for prostate request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}